Get the Stockscreener App
3.69
16.40%
0.52
Pre-market:
3.75
0.06
+1.63%
Esperion Therapeutics Inc stock is traded at $3.69, with a volume of 19.15M.
It is up +16.40% in the last 24 hours and up +36.16% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$3.17
Open:
$3.28
24h Volume:
19.15M
Relative Volume:
2.69
Market Cap:
$882.14M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.7406
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+30.39%
1M Performance:
+36.16%
6M Performance:
+366.91%
1Y Performance:
+43.58%
1-Day Range:
$3.28
$3.77
1-Week Range:
$2.735
$3.77
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.69 | 751.51M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
127.89 | 54.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.50 | 44.92B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.06B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.99 | 28.42B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
485.77 | 20.55B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Therapeutics: Soaring Momentum Observed - StocksToTrade
Esperion a new overweight at Piper Sandler on CV franchise - Seeking Alpha
Esperion’s Strategic Moves: What It Means? - StocksToTrade
Why Analysts Are Rewriting Esperion’s Story After New Pipeline Results and Global Partnerships - Yahoo Finance
Esperion gains after Piper Sandler initiates with 'overweight' rating - TradingView
Piper Sandler initiates Esperion Therapeutics stock with Overweight rating By Investing.com - Investing.com Nigeria
United StatesGoodwin Advises Esperion On $75 Million Underwritten Public Offering - Mondaq
Piper Sandler initiates Esperion Therapeutics stock with Overweight rating - Investing.com India
Esperion shares rise as Otsuka launches NEXLETOL in Japan By Investing.com - Investing.com Nigeria
Esperion Therapeutics Partner Rolls Out Nexletol Tablets in Japan to Treat Hypercholesterolemia - MarketScreener
Esperion stock rises after $90 million payment from Japan launch By Investing.com - Investing.com Australia
Esperion stock rises after $90 million payment from Japan launch - Investing.com
Is Esperion Therapeutics Inc. stock undervalued vs historical averages2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Esperion shares rise as Otsuka launches NEXLETOL in Japan - Investing.com India
Esperion partner Otsuka launches Nexletol in Japan - MarketScreener
Esperion Partners with Otsuka to Launch NEXLETOL in Japan, Secures $90 Million Payment - Quiver Quantitative
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia - The Manila Times
Esperion (NASDAQ: ESPR) earns $90M with Otsuka's NEXLETOL launch in Japan market - Stock Titan
Is Esperion Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Will Esperion Therapeutics Inc. stock recover faster than marketTreasury Yields & Daily Profit Focused Screening - newser.com
Why retail investors favor Esperion Therapeutics Inc. stock2025 Big Picture & High Conviction Buy Zone Picks - newser.com
Esperion: HLS Therapeutics (TSX:HLS) Secures Health Canada Clearance for NILEMDO® - Kalkine Media
Why Esperion Therapeutics Inc. is moving todayMarket Movement Recap & Expert Verified Movement Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.Portfolio Return Summary & Low Drawdown Momentum Ideas - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersQuarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Esperion (NASDAQ: ESPR) to Present at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Can Esperion Therapeutics Inc. stock double in next 5 yearsJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Esperion’s cholesterol drug Nilemdo receives Health Canada approval By Investing.com - Investing.com Nigeria
Esperion’s cholesterol drug Nilemdo receives Health Canada approval - Investing.com
Esperion partner announces HLS Therapeutics received approval of Nilemdo for the reduction of LDL cholesterol in Canadians at risk of cardiovascular disease - MarketScreener
Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease - TradingView
HLS Therapeutics Receives Health Canada Approval to Market NILEMDO® for LDL-Cholesterol Reduction in Partnership with Esperion - Quiver Quantitative
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - The Manila Times
Esperion (NASDAQ: ESPR) HLS secures Health Canada approval for NILEMDO launch Q2 2026 - Stock Titan
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
[Form 3] Esperion Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Relative strength of Esperion Therapeutics Inc. in sector analysisInflation Watch & Breakout Confirmation Alerts - newser.com
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.83%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):